• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病、幽门螺杆菌属和肠道微生物组。

NAFLD, Helicobacter species and the intestinal microbiome.

机构信息

School of Biotechnology and Biomolecular Sciences, UNSW Sydney, Sydney, NSW, 2052, Australia.

School of Biotechnology and Biomolecular Sciences, UNSW Sydney, Sydney, NSW, 2052, Australia.

出版信息

Best Pract Res Clin Gastroenterol. 2017 Dec;31(6):657-668. doi: 10.1016/j.bpg.2017.09.008. Epub 2017 Sep 5.

DOI:10.1016/j.bpg.2017.09.008
PMID:29566909
Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. It is well-accepted that gut dysbiosis is associated with NAFLD, however, there is some conflicting evidence regarding the nature of these alterations. Infection with Helicobacter species, mainly H. pylori, has also been associated with increased NAFLD risk, however, some studies have failed to reproduce this finding. Further studies including large study samples and standardised procedures for microbiota analyses, H. pylori detection and NAFLD diagnostic criteria, are required. The mechanisms involving Helicobacter species and the intestinal microbiome in NAFLD pathogenesis appear to be part of the multiple-hit theory, in which increased intestinal permeability, inflammatory responses, altered choline, bile acids and carbohydrate metabolism, production of short-chain fatty acids, urea cycle and urea transport systems, altered maintenance of hepatic γδT-17 cells, insulin resistance, hormones secreted by the adipose tissue, metabolic hormones, bacterial metabolites and Helicobacter toxins, are all implicated.

摘要

非酒精性脂肪性肝病(NAFLD)已成为全球最常见的慢性肝病。人们普遍认为肠道菌群失调与 NAFLD 有关,但关于这些变化的性质仍存在一些相互矛盾的证据。感染幽门螺杆菌(Helicobacter species),主要是 H. pylori,也与增加的 NAFLD 风险相关,但一些研究未能重现这一发现。需要进一步的研究,包括大样本研究和标准化的微生物组分析、H. pylori 检测和 NAFLD 诊断标准的程序。涉及 Helicobacter 物种和肠道微生物组在 NAFLD 发病机制中的机制似乎是多因素理论的一部分,其中包括增加的肠道通透性、炎症反应、胆碱、胆汁酸和碳水化合物代谢改变、短链脂肪酸的产生、尿素循环和尿素转运系统、肝 γδT-17 细胞的维持改变、胰岛素抵抗、脂肪组织分泌的激素、代谢激素、细菌代谢物和 Helicobacter 毒素。

相似文献

1
NAFLD, Helicobacter species and the intestinal microbiome.非酒精性脂肪性肝病、幽门螺杆菌属和肠道微生物组。
Best Pract Res Clin Gastroenterol. 2017 Dec;31(6):657-668. doi: 10.1016/j.bpg.2017.09.008. Epub 2017 Sep 5.
2
Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.肠道激素、肠道微生物群与非酒精性脂肪性肝病
Minerva Endocrinol. 2017 Jun;42(2):184-194. doi: 10.23736/S0391-1977.16.02567-0. Epub 2016 Nov 23.
3
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.槲皮素对高脂饮食诱导的小鼠非酒精性脂肪性肝病的保护作用是通过调节肠道微生物群失衡和相关肠-肝轴激活来介导的。
Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25.
4
Helicobacter pylori and non-alcoholic fatty liver disease: A new enigma?幽门螺杆菌与非酒精性脂肪性肝病:新的谜团?
Helicobacter. 2018 Dec;23(6):e12537. doi: 10.1111/hel.12537. Epub 2018 Sep 23.
5
Microbiota, Obesity and NAFLD.微生物组、肥胖和非酒精性脂肪性肝病。
Adv Exp Med Biol. 2018;1061:111-125. doi: 10.1007/978-981-10-8684-7_9.
6
Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.靶向肠道微生物组治疗非酒精性脂肪性肝病的机制和治疗进展。
Front Med. 2018 Dec;12(6):645-657. doi: 10.1007/s11684-018-0645-9. Epub 2018 Sep 4.
7
[Microbiome & NASH - partners in crime driving progression of fatty liver disease].[微生物群与非酒精性脂肪性肝炎——推动脂肪性肝病进展的罪魁祸首]
Z Gastroenterol. 2019 Jul;57(7):871-882. doi: 10.1055/a-0755-2595. Epub 2019 Jul 9.
8
The role of the gut microbiota in NAFLD.肠道微生物群在非酒精性脂肪性肝病中的作用。
Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412-25. doi: 10.1038/nrgastro.2016.85. Epub 2016 Jun 8.
9
Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease.靶向肠道微生物群治疗非酒精性脂肪性肝病
Curr Drug Targets. 2015;16(12):1324-31. doi: 10.2174/1389450116666150416120351.
10
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?益生菌在非酒精性脂肪性肝病中的作用:肠道微生物组是否重要?
Nutrients. 2019 Nov 19;11(11):2837. doi: 10.3390/nu11112837.

引用本文的文献

1
Clinical and biochemical characterization of hepatitis B surface antigen-positive patients with or without co-infection at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia.埃塞俄比亚西北部贡德尔大学综合专科医院乙肝表面抗原阳性合并或未合并感染患者的临床与生化特征
Front Immunol. 2025 Jun 18;16:1553411. doi: 10.3389/fimmu.2025.1553411. eCollection 2025.
2
Associations of with metabolic dysfunction-associated steatotic liver disease and related conditions: cross-sectional results from the Hispanic Community Health Study/Study of Latinos.[具体因素]与代谢功能障碍相关脂肪性肝病及相关病症的关联:西班牙裔社区健康研究/拉丁裔研究的横断面结果
Lancet Reg Health Am. 2024 Nov 30;41:100953. doi: 10.1016/j.lana.2024.100953. eCollection 2025 Jan.
3
Fructooligosaccharides enhance the therapeutic effect of xiao-zhi-fang on non-alcoholic fatty liver disease via regulating intestinal flora.低聚果糖通过调节肠道菌群增强消脂方对非酒精性脂肪性肝病的治疗作用。
Liver Res. 2021 Jun 29;5(4):217-223. doi: 10.1016/j.livres.2021.06.003. eCollection 2021 Dec.
4
Changes in Gut Microbial Composition and DNA Methylation in Obese Patients with NAFLD After Bariatric Surgery.肥胖非酒精性脂肪性肝病患者行减重手术后肠道微生物组成和 DNA 甲基化的变化。
Int J Mol Sci. 2024 Oct 26;25(21):11510. doi: 10.3390/ijms252111510.
5
Association between Helicobacter pylori infection, MASLD, and liver fibrosis in patients with severe obesity: a single-center experience.严重肥胖患者中幽门螺杆菌感染、MASLD 和肝纤维化之间的关系:单中心经验。
Surg Endosc. 2024 Nov;38(11):6873-6879. doi: 10.1007/s00464-024-11177-z. Epub 2024 Aug 27.
6
Identification and validation of cuproptosis-related molecular clusters in non-alcoholic fatty liver disease.鉴定和验证非酒精性脂肪性肝病中与铜死亡相关的分子簇。
J Cell Mol Med. 2024 Feb;28(3):e18091. doi: 10.1111/jcmm.18091. Epub 2024 Jan 3.
7
Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets.胆汁酸与非酒精性脂肪性肝炎:分子机制与治疗靶点
J Adv Res. 2024 May;59:173-187. doi: 10.1016/j.jare.2023.06.009. Epub 2023 Jun 23.
8
Small Intestinal Bacterial Overgrowth and Non-Alcoholic Fatty Liver Disease: What Do We Know in 2023?小肠细菌过度生长与非酒精性脂肪性肝病:2023 年我们了解多少?
Nutrients. 2023 Mar 8;15(6):1323. doi: 10.3390/nu15061323.
9
Impact of Infection on the Pathogenesis and Management of Nonalcoholic Fatty Liver Disease.感染对非酒精性脂肪性肝病发病机制及治疗的影响
J Clin Transl Hepatol. 2023 Jun 28;11(3):670-674. doi: 10.14218/JCTH.2022.00362. Epub 2023 Jan 19.
10
Influence of non-alcoholic fatty liver disease on non-variceal upper gastrointestinal bleeding: A nationwide analysis.非酒精性脂肪性肝病对非静脉曲张性上消化道出血的影响:一项全国性分析。
World J Hepatol. 2023 Jan 27;15(1):79-88. doi: 10.4254/wjh.v15.i1.79.